792
Participants
Start Date
September 7, 2011
Primary Completion Date
September 30, 2013
Study Completion Date
September 2, 2013
Live, attenuated dengue serotype 1, 2, 3, and 4 virus
0.5 mL, subcutaneous at age 12, 18, and 24 months
Yellow fever vaccine
0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
Measles, mumps, and rubella (MMR) vaccine
0.5 mL, subcutaneous at age 12 to 13 months.
Pneumococcal Conjugated Vaccine
0.5 mL, intramuscular at age 13 to 14 months
Hepatitis A Pediatric Vaccine
0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
0.5 mL, intramuscular at age 19 to 20 months
Live, attenuated dengue serotype 1, 2, 3, and 4 virus
0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
Yellow Fever Vaccine
0.5 mL, subcutaneous at age 12 to 13 months
Placebo (NaCl)
0.5 mL, subcutaneous at age 12 to 13 months
Measles, mumps, and rubella vaccine
0.5 mL, subcutaneous at age 13 to 14 months
Pneumococcal Conjugated Vaccine
0.5 mL, intramuscular at age 13 to 14 months
Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
0.5 mL, intramuscular at age 19 to 20 months
Hepatitis A Pediatric Vaccine
0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
Santiago de Cali
Lima
Sanofi Pasteur, a Sanofi Company
INDUSTRY